Printer Friendly

The PPAR[alpha]/[gamma] agonist, tesaglitazar, improves insulin mediated switching of tissue glucose and free fatty acid utilization in vivo in the obese Zucker rat.

1. Introduction

Impaired trafficking of fatty acids between oxidative disposal in nonadipose tissues and storage in adipose tissue, leading to ectopic lipid accumulation, may be causative in impaired glucose control [1], dyslipidemia [2], and inflammation [3], all important factors in the etiology of type 2 diabetes and cardiovascular disease. Metabolic flexibility is defined as the ability to switch from predominantly lipid metabolism, with high fluxes of fatty acids in the fasting state, to enhanced glucose uptake, oxidation and storage under hyperinsulinemic conditions [4]. Impaired metabolic flexibility could in theory induce ectopic lipid accumulation either via defective control of fatty acid availability due to insulin resistance [5, 6] or impaired fatty acid oxidation capacity [7, 8] or both.

Whatever the precise pathophysiological mechanism, it has been shown that lowering fatty acid availability by suppressing 24 h FFA levels, using short term intensive treatment with the nicotinic acid analog acipimox, induced substantial improvements in blood glucose control in patients with type 2 diabetes [9]. While this validates the pharmacodynamic principle of FFA lowering, unfortunately tachyphylaxis towards the FFA lowering effect prevents this nicotinic acid analog from providing a robust and durable therapy for improving glucose control [9, 10]. An alternative approach to reducing ectopic lipid accumulation might be to enhance local fatty acid oxidation. This could be done either by forcing FFA oxidation (e.g., by inhibiting acetyl-CoA carboxylase 2 [11]) or by increasing the capacity to oxidize fatty acids (e.g., by increasing mitochondrial mass) potentially allowing larger physiological increments in oxidation. The approach of increasing fatty acid oxidation to achieve improved glucose control is however speculative because of the potential for accelerated lipid oxidation to inhibit glucose metabolism [12], and final judgment about the usefulness of such a pharmacodynamic principal awaits critical clinical evidence. Peroxisome proliferator-activated receptor (PPAR) [gamma] agonists, thiazolidinediones, are used for the treatment of type 2 diabetes [13], and PPAR[alpha] agonists belonging to the fibrate class of compounds are used for the treatment of dyslipidemias [14]. Here we wanted to test the concept that a combined PPAR[alpha]/[gamma] agonist could improve metabolic flexibility in a widely used animal model of insulin resistance and dyslipidemia associated with obesity, the fa/fa Zucker rat. For this purpose we used tesaglitazar which binds and activates PPAR[alpha] and PPAR[gamma] [15] and was under clinical investigation for its ability to correct disorders of glucose and lipid metabolism. We previously established that this agent increases whole body glucose metabolic insulin action in the obese Zucker rat [16, 17] but the tissue locus of this effect has not been reported. Using tracer methods, the present study provides a comprehensive insight into in vivo glucose and FFA fluxes, as well as, metabolic fate at the whole body and individual tissues levels. The results demonstrate both a profound metabolic inflexibility in the untreated obese Zucker rats compared with the lean control animals and a remarkable ability of tesaglitazar to restore insulin mediated fuel switching in these animals.

2. Materials and Methods

2.1. Animals. Experimental procedures were approved by the Local Ethics Review Committee on Animal Experiments (Goteborg region). Male, 8-wk-old Zucker rats (Charles River Wiga GmbH, Suffield, Germany) were individually housed in a temperature-(20-22[degrees]C) and humidity-controlled (40-60% RH) facility with a 12h light-darkcycle (lights on 06:00) and had free access to rodent chow (R3, Lactamin AB, Stockholm, Sweden) and tap water. At the time of the acute tracer studies (see below), rats were 12-15 wks of age.

2.2. Groups. The following groups of lean (Fa/?) and obese (fa/fa) Zucker rats were studied: lean untreated controls (Lean), obese untreated controls (Obese), and obese treated with tesaglitazar 3 [micro]mol/kg/day (Tesaglitazar) for 3 weeks. This dose gives a close to maximal plasma glucose, insulin and triglyceride lowering in ob/ob mice 16]. Tesaglitazar was dosed daily at 13:00 for 3 wk by oral gavage. Untreated control rats were also gavaged according to the same schedule with an equal volume of vehicle (0.5% carboxymethyl cellulose, 2.5mL/kg).

2.3. Preparation of Animals for Tracer Experiments. On the day of the tracer experiments animals were placed in a clean cage, without food but with continued access to water, at 07:00 h, and the final substance/vehicle gavage was given. Animals were weighed and anesthetized at ~09:00 h (thiobutabarbital sodium salt, Inactin, RBI, Natick, MA; lean 120, obese 180 mg x [kg.sup.-1], i.p.). Rats were tracheotomized with PE 240 tubing and breathed spontaneously. One catheter (PE 50 tubing) was placed in a carotid artery for blood sampling and recording of arterial blood pressure and heart rate. Up to five catheters (PE 10) were placed together in one jugular vein for infusions of tracers, insulin, and glucose and for administering top-up doses of anesthetic, if needed. The catheters were filled with Na citrate solution (20.6 mM) in normal saline to prevent clotting. The arterial catheter patency was maintained by continuous infusion of Na citrate (20.6 mM in saline, 5 [micro]L/min) from shortly after carotid catheterization until the conclusion of the experiment. Body temperature was monitored using a rectal thermocouple and maintained at 37.5[degrees]C by means of servo controlled external heating. A stabilization period of ~150 min elapsed between completion of the surgical preparation and commencement of metabolic studies at ~12:00 h.

2.4. Isoglycemic-Hyperinsulinemic Clamp Studies. The target clamp blood glucose level was determined for each animal to be equal to its own basal blood glucose level (average of at least 3 stable consecutive samples over a 20 min period commencing at least 130 min after completion of surgery). Human insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) was infused at a constant rate based on lean body mass estimated according to [17] via a dedicated jugular vein catheter using a syringe pump (CMA1100, Carnegie Medicin, Solna, Sweden). Arterial blood glucose was measured every 5 min using a glucose analyzer (YSI Incorporated, Yellow Springs, OH, USA; 15 [micro]L blood per sample). Blood glucose was clamped at the basal level (isoglycemia) with a variable rate infusion of 20% (w: v) glucose, using a syringe pump (Model 22I/W, Harvard Apparatus Inc., South Natic, MA, USA) via a dedicated jugular vein catheter. Steady state in both blood glucose level (within [+ or -] 10% of the target level) and glucose infusion rate (GIR) was generally achieved within 60 min of clamp start.

Clamps were performed at different plateau levels of hyperinsulinemia from physiologically relevant to supraphysiological. Those denoted ClampL were performed at levels of hyperinsulinemia that were physiologically relevant for the particular group under study. In this case insulin infusion rates were tailored for each of the three groups of Zucker rats to produce plateau insulin levels corresponding to those observed in the freely fed postprandial state (2 h after onset of the dark phase) as determined in separate experiments: Lean 30, Obese 120, and Tesaglitazar 60 pmol/[kg.sub.lbm]/min. To obtain information about insulin responsiveness ClampH clamps were performed at supraphysiological levels of hyperinsulinemia, with insulin infused at 10 times the corresponding ClampL rates for each group, that is, Lean 300, Obese 1200, and Tesaglitazar 600 pmol/[kg.sub.lbm]/min. An additional ClampM was performed only in the Tesaglitazar group with an insulin infusion rate at 210 pmol/[kg.sub.lbm]/min to achieve a plasma insulin level corresponding to the postprandial levels seen in the Obese group.

2.5. Study Outlines

Study 1: Effects of Hyperinsulinemia in the Physiological Range on Whole Body Glucose Disposal ([R.sub.d]) and Hepatic Glucose Output (HGO). Each animal was studied during a basal phase, immediately followed by a clamp phase.

Basal Phase. D-[3, [sup.3]H]glucose ([sup.3]H-glucose, Amersham Pharmacia Biotech, Uppsala, Sweden) was administered as an initial 2 min priming infusion (~30 x [10.sup.6] dpm/kg) followed by a constant infusion (1 x [10.sup.6] dpm/min/kg). Arterial blood samples (~100 [micro]L) were collected at 40, 60, 70, and 80 min following commencement of tracer administration directly from the carotid catheter into potassium EDTA containing tubes (Microvette CB300, Sarstedt, NUmbrecht, Germany), for determination of plasma [sup.3]H-glucose (see below) and plasma glucose levels using a YSI 2700 glucose analyzer (YSI Incorporated, Yellow Springs, OH, USA). Samples collected at 60, 70, and 80 min were used to define the basal phase plasma [sup.3]H-glucose steady state and the subsequent target blood glucose level for the clamp state.

Clamp Phase. Beginning after collection of the 80 min sample, insulin was infused at rates that were needed to perform ClampL clamps (defined previously). Arterial blood glucose was clamped at the basal level using the methods described previously. Arterial blood samples collected at ~120, 140, 150, and 160 min following commencement of the tracer administration were used to estimate the clamp phase [sup.3]H-glucose steady state. Additional plasma (~50 [micro]L) was collected (during the basal phase at 80 min and during the clamp phase at 160 min) and stored at -20[degrees]C for later determination of glucose, insulin, free fatty acids (FFA), and triglycerides (TG).

Study 2: Insulin Action in the Nonhepatic Tissues. The dependence of tissue specific glucose utilization ([R'.sub.g]) on insulin was assessed in Lean, Obese, and Tesaglitazar groups by making separate studies in the basal state (Basal), as well as under ClampL and ClampH conditions (defined previously). In addition the Tesaglitazar group was studied under ClampM conditions.

Isoglycemic-hyperinsulinemic clamp studies were performed according to the methods detailed previously. 2-deoxy-D-[2,6-[sup.3]H]glucose (3H-2DG, Amersham Pharmacia Biotech) was administered as an intravenous bolus (~8 x [10.sup.7] dpm) following attainment of clamp steady state, 60 min after commencement of the insulin infusion (clamp studies), or in the case of basal studies after collection of the basal blood sample. Blood samples for determination of plasma tracer concentration were collected according to the sampling schedule described in [18]. Estimates of the whole body rate of glucose disposal ([R'.sub.d]) were obtained from the plasma disappearance of [sup.3]H-2DG, after correction for urinary excretion [19]. [R'.sub.g] was calculated from the tissue accumulation of [sup.3]H-label, essentially as described in [18]. Immediately following collection of the final blood sample (45 min after tracer administration) rats were given an overdose of thiobutabarbital (120 mg/kg). Samples of the following tissues were collected: white quadriceps muscle (WQ), red quadriceps (RQ), red gastrocnemius (RG), epididymal adipose tissue (white fat), interscapular brown adipose tissue (brown fat), diaphragm, heart, and cerebellum. For measurement of total [sup.3]H-label content, freshly collected tissue pieces were weighed and placed in small cardboard cones for combustion (see below). Two blood samples (150 [micro]L each) were collected; plasma was separated and stored at -20[degrees]C for later determination of steady state plasma glucose, insulin, and FFA concentrations: one was collected just prior to the tracer bolus, the other 45 min after the tracer bolus.

Study 3: Metabolic Flexibility. In order to assess the influence of physiological changes in insulin level on metabolic switching of glucose and FFA fuels, animals were studied in either the Basal or ClampL states (defined previously). In this study a number of whole body and tissue specific glucose and FFA fluxes were evaluated: an estimate of [R.sub.d], ([[??].sub.d]), rate of plasma FFA appearance ([R.sub.fa]), [R'.sub.g], glycogen synthesis rate ([R.sub.gly]), tissue FFA utilization index ([R.sup.*.sub.f]), and rate of FFA incorporation into storage ([R.sub.fs]). The tracer experiment began following collection of a basal blood sample (Basal study) or attainment of clamp steady state (Clamp study). A bolus (~400 [micro]L) containing D-(U-[sup.13]C) glucose ([sup.13]C-glucose, ~6 mg, Cambridge Isotope Laboratories, Inc., Andover, MA) and 2-deoxy-D-[U-[sup.14]C] glucose ([sup.14]C-2DG, ~5 x [10.sup.7] dpm, Amersham, Solna, Sweden) was injected intravenously via a dedicated jugular catheter and arterial blood samples (75 [micro]L) were collected at 2, 5, 10, 15, 20, and 25 min. Then at 30 min an albumin-palmitate-fatty acid tracer complex was infused via another dedicated jugular catheter at 230 [micro]L/min for a total of 4 min as described in [20]. Two fatty acid tracers were included; (1) the partially-metabolizable analogue [9, 10-[sup.3]H]-(R)-2- bromopalmitate ([sup.3]H-R-BrP, ~5 x [10.sup.7] dpm, synthesized and purified as described in [21]) and (2) [U-[sup.14]C]-palmitic acid ([sup.14]C-P, ~2.5 x [10.sup.7] dpm; Amersham, Solna, Sweden). Additional arterial blood samples (75 [micro]L) were collected at 31, 32, 33, 34, 35, 36, 38, 42, and 46 min with respect to the glucose tracer bolus. Blood samples were centrifuged at 4[degrees]C, and two plasma aliquots were pipetted: 25 [micro]L into 2 mL extraction mixture (for determination of 14C-2DG, 13C-glucose, [sup.3]H-R-BrP, and [sup.14]C-P levels) and 10 [micro]L onto a cellulose cone for combustion (for determination of total [sup.3]H and [sup.14]C-levels, see below). After collection of the final blood sample rats were given an overdose of thiobutarbital, and tissues were rapidly dissected and frozen in liquid [N.sub.2]. Tissue samples were stored at -80[degrees]C awaiting analysis for tracer content (see below) and in the case of red skeletal muscle, glycogen content as well.

2.6. Determination of Tissue and Plasma Tracer Concentrations

Study 1. Plasma [sup.3]H-glucose concentration was determined by pipetting 25 [micro]L freshly collected plasma directly into ice chilled 100 [micro]L 0.15 M ZnS[O.sub.4]. Then 100 [micro]L of 0.15 M Ba[(OH).sub.2] was added, the tube vortexed, and centrifuged, and an aliquot of the supernatant was counted following evaporation (70[degrees]C, [N.sub.2]), reconstitution in 0.5 mL water and addition of 5mL scintillant.

Study 2. Plasma [sup.3]H-2DG concentration and tissue [sup.3]H-activity were determined based on the production of [sup.3][H.sub.2]O by completely oxidizing the 25 [micro]L plasma samples and -100 mg tissue pieces using a Packard System 387 Automated Sample Preparation Unit (Packard Instrument Co. Inc., Meriden, CT).

Study 3. Freshly collected plasma (25 [micro]L) was pipetted directly into glass test tubes with 2 mL isopropanol: heptane: 1M acetic acid (40: 10 : 1 vol). Plasma extraction was performed according to [22] with the exception that sulphuric acid was replaced with 1M acetic acid. [sup.14]C-P and [sup.3]H-R-BrP, as well as esterified fatty acids, were quantitatively removed in the upper, heptane phase, while [sup.13]C-glucose and [sup.14]C-2DG, as well as polar metabolites and [sup.3][H.sub.2]O, were quantitatively recovered in the lower aqueous phase. Upper phase polar lipids (including [sup.14]C-P and [sup.3]H-R-BrP) were separated from neutral lipids (including endogenously esterified [sup.14]C-P) by means of solid phase extraction (200 mg N[H.sub.2] columns, Isolute, Sorbent AB, Goteborg, Sweden). Retained polar lipids were driven off the columns using 5% glacial acetic acid in methyl-tert-butyl ether. The effluent was mixed with scintillant and counted for determination of [sup.14]C-P and [sup.3]H-R-BrP. Two aliquots of the lower phase were taken: one counted for total [sup.14]C-content (used to determine [sup.14]C-2DG); a second for determination of [sup.13]C-glucose. For the latter aliquot, glucose was derivatized to aldonitrile penta acetate using hydroxylamine in pyridine and acetic anhydride. The glucose derivative was dissolved in ethyl acetate after evaporation to dryness and analysed by gas-chromatography-isotope ratio-mass spectrometry using a Hewlett Packard 6890 gas chromatogram (GC) connected to an isotope ratio mass spectrometer (Finnigan Delta Plus, Finnigan, San Jose, CA) via a Finnigan GC Combustion III interface. The [sup.13]C/[sup.12]C ratio of the formed C[O.sub.2] was compared with results for a [sup.13]C-glucose enriched linear calibration curve and tracer to tracee ratios (TTR) for [sup.13]C to [sup.12]C[O.sub.2] were calculated. Tissue samples were homogenized and extracted in ice chilled glassglass homogenizers, essentially according to [23]. The organic phase was quantitatively recovered for determination of [sup.3]H- and [sup.14]C-labelled lipids. Aliquots of the aqueous phase were taken for determination of (1) total polar [sup.3]H- and [sup.14]C-labelled metabolites and (2) [sup.14]C-labelled anion, by solid phase extraction (200 mg PE-AX columns, Isolute) assumed to be phosphorylated [sup.14]C-2DG. Separate tissue pieces were used for determination of glycogen content based on the glycogen precipitation (KOH/ethanol) method and enzymatic conversion to glucose [24]. Aliquots of the resulting glucose solution were taken for (1) measurement of glucose concentration using the colorimetric kit method and (2) analysis of 13Cglucose as described previously for plasma.

Except for samples generated by the oxidizer, the scintillant used to make the cocktails for counting was Optiphase Hisafe III (Perkin Elmer, Upplands Vasby, Sweden). Sample disintegrations per minute were estimated using a Wallac 1409 counter (Wallac OY, Turku, Finland).

2.7. Measurement of Plasma Lipids, Glucose, and Insulin. Colorimetric kit methods were used to measure plasma FFA (NEFA C, Wako, Richmond, VA), and glucose (Glucose HK, Roche, Stockholm, Sweden). Plasma TG was also determined using a colorimetric method by measuring the glycerol released by complete enzymatic hydrolysis of triglycerides (Triglycerides/GB, Boehringer Mannheim, Indianapolis, IN). Colorimetric measurements were performed on a centrifugal analyzer (Cobas Bio, F. Hoffmann-La Roche & Co., Basle, Switzerland). Radioimmunoassays were used to measure plasma concentrations of insulin (Rat Insulin RIA Kit, Linco Research Inc., St. Charles, MO, USA).

2.8. Calculations

Study 1. [R.sub.d] was estimated, assuming attainment of steady state, from the measured plateau plasma [sup.3]H-glucose concentration ([c.sub.P]) and corresponding measured plasma glucose concentration ([C.sub.P]) using [R.sub.d] = I x [C.sub.P]/[c.sub.P] where I is tracer infusion rate. The reported basal Rd value represents the average of the 60, 70, and 80 min estimates. The reported clamp Rd value was calculated from the average of the 140, 150, and 160 min estimates. During the basal phase, HGO was calculated as HGO = [R.sub.d]. During the clamp phase HGO was calculated as HGO = [R.sub.d] - GIR, where GIR is the steady state glucose infusion rate.

Study 2. An index of the whole body rate of glucose disposal ([R'.sub.d]) was calculated from the plasma disappearance of 3H2DG according to [19]. [R'.sub.g] was calculated from plasma kinetics of [sup.3]H-2DG and tissue retention of phosphorylated [sup.3]H-2DG based on the methods described in [18]. Note that [R'.sub.g] data for the liver is not presented due to poor metabolic trapping of 2DG in this tissue [ 25]. Tissue level insulin action was assessed quantitatively in a particular group by fitting [R'.sub.g] versus plasma insulin level ([Ins]) results for individual animals to a dose-response curve; that is,

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII], (1)

where [R'.sub.g](min) is the asymptotic value of [R'.sub.g] estimated as [Ins] [right arrow] 0, [R'.sub.g] (max) is the asymptotic value of [R'.sub.g] as [Ins] [right arrow] [infinity], [EC.sub.50] is the [Ins] required to affect a half maximal response; that is, ([R'.sub.g] (min) + [R'.sub.g](max))/2, b is a slope factor. Note that [EC.sub.50] is the strict quantitative definition of insulin sensitivity, and the difference, [R'.sub.g] (max) - [R'.sub.g] (max), is the insulin responsiveness.

Study 3. Plasma FFA clearance rate ([K.sub.fa]) and appearance rate ([R.sub.fa]) were calculated from plasma 14C-P kinetics according to previously described methods [20]. Indices of utilization rates of plasma substrate by tissues (R), specifically [R'.sub.g], [R.sub.gly], [R.sup.*.sub.f], and [R.sub.fs] were calculated based on [sup.14]C-2DG, [sup.13]C-glucose, [supp.3]H-R-BrP, and [sup.14]C-P, respectively from the general relation:

R = C x [m.sup.*]/[[integral].sup.T.sub.0][c.sup.*](t)dt, (2)

where C is the plasma substrate concentration (glucose or FFA), t is time, T is the time of tissue collection, [m.sup.*] is the tissue accumulation of tracer product at t = T, and [c.sup.*](t) is the plasma tracer concentration.

[[??].sub.d] was obtained from the plasma disappearance of [sup.13]C- glucose/[sup.12]C-glucose ratio above natural abundance (c) based on the following equation:

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]. (3)

where Dose is the bolus dose of [sup.13]C-glucose (in [micro]mol), [??] was calculated from the equation [??] = 16/6 x (TTR - [TTR.sub.na]), [TTR.sub.na] = 0.0112372, and the integral was calculated using best fit parameters obtained by fitting a double exponential to the disappearance data. This estimate of [[??].sub.d] does not have the same accuracy as the gold standard tracer steady state method applied in Study 1.

The whole body and tissue specific glucose and FFA flux indices for all studies are summarized in Table 1.

2.9. Statistics. Analysis of group data was based on contrasts to specifically test the principle a priori questions of the study: Lean versus Obese (obesity effect) and Tesaglitazar versus Obese (treatment effect). Analysis of Study 3 was based on detection of the above between group difference in the basal state and the responses to insulin (ClampL-Basal). The latter was interpreted as a measure of metabolic flexibility. Statistical significance of the contrasts were evaluated on the basis of F-tests using the program SPSS (SPSS Inc., Chicago, IL). Results are reported as means [+ or -] SE. P < 0.05 was considered statistically significant.

3. Results

3.1. Study 1: Effects of Hyperinsulinemia, in the Physiological Range, on Whole Body Glucose Disposal and HGO. Three groups of age matched animals were studied: vehicle treated lean (Lean) and obese Zucker (Obese) controls and obese Zuckers treated with tesaglitazar, 3 [micro]mol/kg/day for 3 weeks (Tesaglitazar). During the treatment period body weight gain was greater in Obese compared to Lean, 4.5 [+ or -] 0.3 versus 2.3 [+ or -] 0.1 g/day, respectively; P < 0.001 and was further increased in Tesaglitazar to 8.3 [+ or -] 0.8 g/day (P < 0.01 versus Obese). Following the 3-week treatment period whole body glucose turnover was studied under basal fasting and ClampL conditions of physiological hyperinsulinemia (see Section 2). Body weights at the time of study as well as steady state glucose levels and GIRs are summarized in Table 2. This data confirms a large tesaglitazar induced increase in whole body insulin action consistent with earlier work [16].

Figure 1 shows the results of the tracer based measurements, whole body glucose disposal (Fd), and hepatic glucose output (HGO) plotted against plasma insulin at basal (fasting) and ClampL levels. Tesaglitazar treatment did not correct the elevation in basal HGO or the associated moderate hyperglycemia of the obese Zucker rat. The afore mentioned treatment induced improvement in whole body insulin action involved both enhanced peripheral insulin action (greater increment in Rd at lower insulin levels compared to Obese) and hepatic insulin sensitization (Figure 1). Estimated insulin concentrations required to suppress HGO to 50% of the basal level ([EC.sub.50]) were substantially reduced in Tesaglitazar 2.4 [+ or -] 0.4 versus Obese 15.4 [+ or -] 5.0 nM, P < 0.05. For comparison the [EC.sub.50] for Lean was 0.65 [+ or -] 0.08 nM.

3.2. Study 2: Insulin Action in the Nonhepatic Tissues. We next wanted to identify the nonhepatic tissues responsible for the tesaglitazar induced enhancement in peripheral insulin action, as well as the roles of insulin sensitivity versus responsiveness. For this purpose, in vivo tissue specific glucose utilization rates ([R'.sub.g]) were assessed using the 2-deoxyglucose tracer method. Dependence of [R'.sub.g] on plasma insulin level was determined by performing studies in the basal fasting state and during glucose clamps performed at physiologic and superphysiological levels of hyperinsulinemia in Lean, Obese, and Tesaglitazar groups. Table 3 summarizes insulin infusion rates and steady state plasma insulin and glucose levels, as well as the GIRs needed to maintain isoglycemia, with results consistent with previous findings and in addition showing that tesaglitazar treatment completely restored insulin's ability to maximally stimulate GIR (responsiveness).

Figure 2 shows insulin's effects on plasma FFA level and whole body [R'.sub.d]. Tesaglitazar treatment did not correct the elevation in basal FFA but induced a remarkable amelioration in the defects in insulin mediated suppression of plasma FFA and stimulation of [R'.sub.d] involving both increased responsiveness (maximum effect) and sensitivity (leftward shift) to insulin.

Indices of glucose utilization rates ([R'.sub.g]) in individual tissues are summarized in Table 4. In the basal state, [R'.sub.g] of the red hindlimb muscle of the Tesaglitazar group was lower than in the Obese group, representing a normalization towards the values in the Lean group. White adipose tissue [R'.sub.g], elevated in Obese versus Lean, was further elevated by tesaglitazar. In all insulin responsive tissues examined (i.e., not cerebellum) tesaglitazar markedly improved the ability of insulin to concentration dependently stimulate [R'.sub.g] in the obese Zucker rat. An example showing the dependence of [R'.sub.g] on plasma insulin is illustrated in Figure 3 for the RQ muscle. This treatment effect was so profound that it enabled quantitative estimation of insulin sensitivity ([EC.sub.50] value for [R'.sub.g] as defined in Section 2) in a number of tissues of the obese rat which was generally not possible in untreated animals due to a virtual absence of insulin effect. For the Tesaglitazar treated group the [EC.sub.50] for white fat, diaphragm and RG were 0.7 nM (95% CI 0.4-1.0), 1.7 nM (1.1-2.7), and 3.5 nM (0.621.4), respectively. (For comparison the [EC.sub.50] values in Lean animals were for white fat, diaphragm, and RG 0.5 nM (95% CI 0.4-0.7), 0.9 nM (0.7-1.2), and 1.4 nM (0.9-2.1), resp.). By contrast in Obese only in white fat could an estimate of [EC.sub.50] be made: 9.6 nM (6.4-14.6). The improvement in insulin action with tesaglitazar treatment was also manifested in a general restoration of insulin responsiveness with [R'.sub.g] at supraphysiologic insulin levels substantially higher in skeletal muscle and white fat (Figure 3 and Table 4) in Tesaglitazar compared to Obese. In the Tesaglitazar group, maximal insulin effects on both whole body glucose metabolism and [R'.sub.g] in insulin responsive tissues were actually generally achieved under ClampM conditions, performed at insulin levels equivalent to those seen postprandially in untreated obese Zuckers (Tables 3 and 4).

3.3. Study 3: Insulin Mediated Switching of Glucose and FFA Fluxes. In the final study whole body and tissue specific FFA metabolism in the three groups were examined in both the basal fasting state and under ClampL conditions of hyperinsulinemia (see Section 2). Furthermore, to evaluate substrate switching in the same experiment, glucose fluxes were also assessed along with FFA fluxes. For this purpose, four tracers were applied in each animal to provide virtually simultaneous information about plasma FFA utilization ([R.sup.*.sub.f]), plasma FFA incorporation into storage ([R.sub.fs]), and glucose utilization ([R'.sub.g]) in a number of tissues. In addition an estimate of glucose incorporation into glycogen synthesis ([R.sub.gly]) was obtained for red skeletal muscle. Table 5 summarizes the whole body parameters for Study 3. The insulin and glucose metabolic data (including an estimate of [R.sub.d]) are consistent with results from Studies 1 and 2, confirming the insulin resistant phenotype of the obese Zucker as well as its amelioration with tesaglitazar.

Whole Body FFA Metabolism. [R.sub.fa] was substantially elevated in Obese compared to Lean confirming an earlier study [26] showing mobilization, rather impaired clearance, to be the main mechanism for fatty acid elevation in obese animals (Table 5). Tesaglitazar's influence on systemic FFA availability was highly dependent on prevailing insulin level. In the basal state plasma FFA levels were similar in Tesaglitazar and vehicle treated obese rats. Interestingly in this situation tesaglitazar treated animals actually exhibited elevated [R.sub.fa] compared to vehicle controls which did not translate into a further elevation in plasma FFA levels due to a treatment induced increase in [K.sub.fa] (Table 5), the combined ability of the tissues of the body to take up FFA. Tesaglitazar profoundly improved insulin's ability to suppress systemic FFA mobilization ([R.sub.fa]), the main mechanism of treatment induced FFA lowering. ClampL FFA levels in the Tesaglitazar group were in fact virtually normalized despite a 2.3-fold higher [R.sub.fa] compared to the Lean group, due to the treatment induced enhancement in [K.sub.fa] (Table 5).

Tissue Specific Metabolism. Figure 4 summarizes tissue specific rates of glucose utilization [R'.sub.g] (left panel), FFA utilization [R.sup.*.sub.f] (middle), and FFA clearance (right). In the top row of this figure are "average tissue" glucose and FFA utilization rates ([R.sub.gav] and [R.sub.fav]) which were obtained from the [[??].sub.d] and [R.sub.fa] data presented in Table 5 corrected for body weight. This data confirms that tesaglitazar treatment markedly ameliorated the impairment in insulin mediated switching of glucose and fatty acid utilization in the obese Zucker at the whole body level. Most importantly, a similar pattern is reflected in the [R'.sub.g] and [R.sup.*.sub.f] profiles for muscle and white fat showing the quantitative importance of these tissues to whole body metabolism.

Tissue Specific FFA Utilization, [R.sup.*.sub.f]. A couple of general features in the data shown in the middle column, Figure 4, are worthy of comment. Firstly, independent of group, the magnitude of [R.sup.*.sub.f] varies widely between the tissues with liver values 2 orders of magnitude higher than those for the cerebellum. Secondly, a similar between group pattern of [R.sup.*.sub.f] was consistently seen in all of the tissues which mirror plasma FFA levels (see Table 5) reflecting the strong influence of substrate supply in driving FFA utilization. Basal [R.sup.*.sub.f] values tended to be higher in Obese animals versus Lean, with little effect of tesaglitazar except in the heart (which showed a lowering, normalization of [R.sup.*.sub.f]). In Obese, there was a widespread failure of insulin to suppress [R.sup.*.sub.f] in strong contrast to the situation in Lean and Tesaglitazar.

Tissue Specific FFA Clearance, [K.sup.*.sub.f]. [K.sup.*.sub.f] is a measure of the local ability of the tissues to utilize FFA. While FFA level was clearly a dominant factor in determining between group differences in [R.sup.*.sub.f] of an individual tissue, the [K.sup.*.sub.f] data (right most column, Figure 4) revealed insulin mediated regulation/dysregulation of FFA utilization at the local tissue level. Thus in Lean tissues, insulin exerted heterogeneous effects on [K.sup.*.sub.f] which were lost in the Obese tissues: stimulation in skeletal muscle and suppression in heart and liver with no significant effect in white fat or cerebellum. Surprisingly, tesaglitazar did not induce normalization of the response to insulin in this parameter in any of the tissues examined. In white fat tesaglitazar induced an increase in [K.sup.*.sub.f] which was potentiated by insulin (Figure 4).

Tissue Specific Nonoxidative FFA Disposal, [R.sub.fs]. While [R.sup.*.sub.f] indexes uptake into both oxidative and nonoxidative disposal, the parameter [R.sub.fs] (summarized in Table 6) represents flux into nonoxidative disposal only. Generally the between group pattern described previously for [R.sup.*.sub.f] was also seen for [R.sub.fs] with these two variables strongly positively correlated (data not shown). In the basal state, tesaglitazar normalized [R.sub.fs] in the heart only with no apparent normalization of the elevated levels in other tissues including skeletal muscle and liver (which in fact was further increased by treatment). This latter result was particularly surprising to us due to the established influence of PPAR[alpha] stimulation in upregulating [beta]-oxidation machinery. Tesaglitazar greatly improved insulin's ability to suppress tissue nonoxidative FFA disposal resulting in normalization of [R.sub.fs] at physiological hyperinsulinemia in all tissues examined.

Glucose Utilization by Individual Tissues, [R'.sub.g]. Overall the [R'.sub.g] results (left column, Figure 4) generally agree with Basal and ClampL results from Study 2 consistent with tesaglitazar induced amelioration of insulin resistance in key insulin target tissues. Moderate differences in absolute [R'.sub.g] levels between the two studies may have been the result of the different methodologies used to assess tissue 2DG tracer retention (see Section 2) with a potentially more accurate method used in the current study. Note that hepatic [R'.sub.g] data is not represented in Figure 4 as the estimates are not valid due to poor metabolic trapping of 2DG in this tissue 25].

Glycogen Synthesis in Red Muscle, [R.sub.gly]. Net glycogen mass and synthesis ([R.sub.gly]), obtained by averaging red gastrocnemius and red quadriceps muscle data, are summarized in Table 6. [R.sub.gly] was close to zero in all groups in the basal fasting state. Tesaglitazar succeeded in completely normalizing the insulin induced increase in [R.sub.gly]. Comparison of the magnitudes of [R'.sub.g] (reflecting the sum of glycolysis and glycogen synthesis) and [R.sub.gly] suggests that the insulin induced increases in [R'.sub.g] in Lean and Tesaglitazar groups involved increases in both glycolysis and glycogen synthesis. In the basal state, tesaglitazar reduced glycogen mass to the levels seen in lean animals (Table 7).

4. Discussion

The whole body glucose and FFA metabolic responses to hyperinsulinemia in lean and obese Zucker rats shown in this study are in many respects analogous to the differences reported a number of years ago between patients with type 2 diabetes and control subjects [27] confirming the relevance of the obese Zucker rat as a preclinical model. Results of the present study extend the metabolic characterization of the obese Zucker rat revealing impaired switching of fatty acid and glucose utilization at the tissue level. In lean Zucker rats, physiological hyperinsulinemia substantially reduced the flux of FFA from plasma into skeletal muscles of diverse fiber composition, heart, adipose tissue, and liver. In strong contrast, raising insulin levels in obese Zucker rats failed to quench fluxes of FFA into the tissues.

It has been shown that tesaglitazar ameliorates insulin resistance in animal models [16, 17], as well as centrally obese/hypertriglyceridemic nondiabetic humans [28, 29] and patients with type 2 diabetes [30]; however, the tissue loci of these effects have not been reported. The present study demonstrates that the tesaglitazar induced whole body insulin sensitization was due to a widespread restoration of insulin action. Thus tesaglitazar greatly increased insulin's ability to suppress HGO (Figure 1) and also restored insulin's ability to stimulate skeletal muscle glucose uptake (Table 4). This latter action was of a profound nature with untreated obese Zuckers lacking any robust dose response relationship between skeletal muscle glucose uptake and insulin level. Treatment succeeded in restoring a clear dose response relationship including a remarkable increase in the maximal insulin responsiveness in skeletal muscle (Figure 3). Not only did tesaglitazar enhance insulin stimulated skeletal muscle glucose uptake but also normalized the rate of insulin stimulated glycogen synthesis in this tissue to that seen in the lean Zuckers (Table 7), albeit at a higher insulin level. The effects of tesaglitazar on augmenting insulin mediated control of hepatic and skeletal muscle glucose metabolism are consistent with the results of a number of studies with other PPAR[gamma] agonists on glucose metabolism in both animal models [31] and even patients with type 2 diabetes [32].

Tesaglitazar also augmented insulin's ability to quench systemic FFA availability and decrease FFA uptake, as well as incorporation into nonoxidative disposal in skeletal muscles, heart and the liver. Putting these effects together with the afore mentioned effects on glucose metabolism, it is apparent that tesaglitazar induced an effective and widespread improvement in the ability of insulin to switch fuel mixture in the tissues. This is illustrated in Figure 4 by the results at the level of the whole body, skeletal muscle, heart, and adipose tissue. Under basal insulin conditions, obese Zucker rats exhibited elevated rates of FFA utilization and storage in the majority of tissues driven by elevated circulating FFA levels, disturbances that were not affected by tesaglitazar (discussed below). The apparent failure of the substance to enhance tissue level FFA oxidation in the basal state (as suggested by unaltered FFA uptake in combination with unaltered FFA incorporation into nonoxidative disposal in skeletal muscle and liver) surprised us based on our expectation that tesaglitazar should increase fatty acid oxidation capacity via PPAR[alpha] activation suggested by previous studies showing tesaglitazar induced hepatic enlargement and upregulation of CYP4A [16, 17]. To further explore the specific potential of PPAR[alpha][up arrow] activation to enhance in vivo FFA oxidation we treated rats with a selective PPAR[alpha] agonist, WY14,643. Despite a substantial (> 2-fold increase) in ex vivo FFA oxidation capacity in the liver we detected no WY14,643 induced enhancement of in vivo FFA oxidation in the basal fasting situation or under conditions of substantially elevated oxidative metabolism induced by the uncoupler dinitrophenol (unpublished observations). On the basis of these results and our recent finding that plasma FFA oxidation is not reduced in obese compared to lean Zucker rats [33], it appears that levels of FFA oxidation, FFA oxidation capacity, and insulin resistance are independent, at least in this model. This is in contrast to the situation reported by some studies in insulin resistant humans where reduced fasting levels of whole body fatty acid oxidation are associated with impairment in skeletal muscle fatty acid oxidation capacity [4].

Many of the beneficial effects of tesaglitazar on glucose and lipid metabolism may be secondary to its effect on FFA exchange in adipose tissue. Specifically, fatty acid overflow into nonadipose tissues is ameliorated by two mechanisms: an enhanced ability of fat tissue to take up FFA [34], as well as a greater ability of postprandial insulin levels to suppress FFA appearance rate (Figure 4, middle panel). This latter effect is probably a result of more effective suppression of FFA release from adipocytes, but perhaps also due to reduced spillover of products of intravascular lipolysis into the systemic circulation. Similar effects on adipose tissue FFA exchange have been observed with a thiazolidinedione [26] but were not observed with a selective PPAR[alpha] agonist (unpublished observations). Whether these actions are mediated via PPAR[gamma] agonism or alternatively more recently suggested molecular targets of thiazolidinediones [35, 36] remains to be determined.

The treatment induced reduction in flux of FFA into hepatic lipid stores at high physiological insulin levels (Table 6) in these habitually hyperphagic/hyperinsulinemic animals would tend to lower local TG synthesis and hepatic TG secretion. Indeed we have previously reported that tesaglitazar (same dose and treatment period as the current study) potently lowers hepatic TG content and hepatic TG secretion in obese Zucker rats [17]. In man a reduction in VLDL TG production is expected to have important antidyslipidemic effects [37]. Reduced hepatic FFA availability might also be a mechanism for the improvement in insulin suppression of HGO [38]. The consequences of lowering fatty acid supply is however unlikely to be limited to the liver. Thus, the marked tesaglitazar induced reduction in FFA flux into skeletal muscles (at hyperinsulinemia) may explain the apparent enhancement in insulin stimulated oxidative glucose disposal in this tissue via the glucose-fatty acid cycle [12]. Furthermore, the reduced muscle FFA flux might also lower accumulation of lipid intermediates potentially reducing interference with insulin signaling [39] which may be the basis for the enhanced insulin stimulated glucose uptake and glycogen synthesis rates.

The effects of tesaglitazar on glucose and lipid metabolism in the obese Zucker rat [16] have generally proven to be predictive of effects in patients with type 2 diabetes [30] and obese/insulin resistant subjects [28, 29, 40], with improvements in glucose tolerance, lipid tolerance, insulin sensitivity, and meal induced FFA lowering, as well as decreased plasma TG levels and decreased apoCIII levels seen in both humans and rodents. One aspect of glucose metabolism that tesaglitazar did not correct in the obese Zucker rats was the defect in basal HGO, substantially elevated in obese compared to lean Zucker rats (Figure 1). This may have been a consequence of the failure of treatment to lower plasma FFA flux into the liver in this state (Figure 4). This was probably a result of the lack of lowering of plasma FFA level in the basal state which represents a clear departure from the response in clinical studies where overnight fasting FFAs were consistently lowered by tesaglitazar [28-30]. One possible explanation may be the relatively short treatment duration in the current study. In response to PPAR[gamma] agonists adipose tissue undergoes cellular remodeling [41], with large insulin resistant fat cells emptying and newly differentiated cells filling with triglycerides before a new steady state is reached. Prior to achieving this new steady state it may be that fasting insulin levels which fall in response to developing treatment induced whole body insulin sensitization are insufficient to normalize FFA release from adipose tissue. In patients with type 2 diabetes, for example, approximately 6 weeks of treatment is required for tesaglitazar to achieve the full glucose lowering effect [30].

The clinical development of tesaglitazar was halted in large part due to concern over treatment induced increases in serum creatinine levels in patients [42]. The impressive effects of this agent on glucose and lipid control in animal models and human subjects, including data suggesting important antiatherogenic effects [43, 44], provide strong support for continuing the search for future pharmacodynamic principals that enhance metabolic flexibility.

In conclusion, we have for the first time assessed in vivo fluxes and metabolic fate of both glucose and FFA at the whole body and individual tissue levels as well as the control of these fluxes by insulin in the obese Zucker rat. The results reveal that defective insulin regulation of metabolism extends beyond glucose control to include profound impairments in control of tissue FFA fluxes in this animal model. In addition it was determined that the improvement in whole body insulin mediated glucose control afforded by the PPAR[alpha]/[gamma] agonist tesaglitazar was due to restoration of insulin's ability to suppress hepatic glucose production and stimulate glucose uptake in skeletal muscle. Beyond glucose control, however, tesaglitazar restored insulin's ability to suppress fatty acid availability and the flux of FFA from plasma into muscles and liver which together with the effects on glucose metabolism resulted in a remarkable improvement in insulin mediated switching of fuel utilization.

http://dx.doi.org/10.1155/2013/305347

Conflict of Interests

The authors are full time employees of AstraZeneca R&D which invented and holds the patent to tesaglitazar. Thus, the authors declare that there is a conflict of interests regarding the publication of this paper.

Acknowledgments

This work is dedicated to the authors' friend and research leader, the late Professor Bengt Ljung, whose wisdom continues to guide them. They gratefully acknowledge Dr. Lennart Svenssons group and Dr. Margit Wettesten for clinical chemistry and tissue analyses, respectively.

References

[1] E. W. Kraegen and G. J. Cooney, "Free fatty acids and skeletal muscle insulin resistance," Current Opinion in Lipidology, vol. 19, no. 3, pp. 235-241, 2008.

[2] U. Julius, "Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia," Experimental & Clinical Endocrinology and Diabetes, vol. 111, no. 5, pp. 246-250, 2003.

[3] A. Kosteli, E. Sugaru, G. Haemmerle et al., "Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue," Journal of Clinical Investigation, vol. 120, no. 10, pp. 3466-3479, 2010.

[4] D. E. Kelley and L. J. Mandarino, "Fuel selection in human skeletal muscle in insulin resistance: a reexamination," Diabetes, vol. 49, no. 5, pp. 677-683, 2000.

[5] J. E. Galgani, C. Moro, and E. Ravussin, "Metabolic flexibility and insulin resistance," American Journal of Physiology: Endocrinology & Metabolism, vol. 295, no. 5, pp. E1009-E1017, 2008.

[6] L. M. Sparks, B. Ukropcova, J. Smith et al., "Relation of adipose tissue to metabolic flexibility," Diabetes Research and Clinical Practice, vol. 83, no. 1, pp. 32-43, 2009.

[7] K. Morino, K. F. Petersen, and G. I. Shulman, "Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction," Diabetes, vol. 55, no. 2, pp. S9-S15, 2006.

[8] D. E. Kelley, "Skeletal muscle fat oxidation: timing and flexibility are everything," Journal of Clinical Investigation, vol. 115, no. 7, pp. 1699-1702, 2005.

[9] A. A. Vaag and H. Beck-Nielsen, "Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus," Acta Endocrinologica, vol. 127, no. 4, pp. 344-350, 1992.

[10] P. M. Davoren, W. Kelly, F. A. Gries, A. Hubinger, C. Whately-Smith, and K. G. M. M. Alberti, "Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus," Metabolism, vol. 47, no. 3, pp. 250-256, 1998.

[11] S. Keil, M. Muller, G. Zoller et al., "Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation," Journal of Medicinal Chemistry, vol. 53, no. 24, pp. 8679-8687, 2010.

[12] P. J. Randle, "Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years," Diabetes-Metabolism Reviews, vol. 14, pp. 263-283, 1998.

[13] G. Derosa and P. Maffioli, "Peroxisome proliferator-activated receptor-(PPAR-) agonists on glycemic control, lipid profile and cardiovascular risk," Current Molecular Pharmacology, vol. 5, pp. 272-281, 2012.

[14] N. Katsiki, D. Nikolic, G. Montalto, M. Banach, D. P. Mikhailidis, and M. Rizzo, "The role of fibrate treatment in dyslipidemia: an overview," Current Pharmaceutical Design, vol. 19, pp. 3124-3131, 2013.

[15] P. Cronet, J. F. W. Petersen, R. Folmer et al., "Structure of the PPAR[alpha] and -[gamma] ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family," Structure, vol. 9, no. 8, pp. 699-706, 2001.

[16] B. Ljung, K. Bamberg, B. Dahllof et al., "AZ 242, a novel PPAR[alpha]/[gamma] agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese zucker rats," Journal of Lipid Research, vol. 43, no. 11, pp. 1855-1863, 2002.

[17] N. D. Oakes, P. Thalen, T. Hultstrand et al., "Tesaglitazar, a dual PPAR[alpha]/[gamma] agonist, ameliorates glucose and lipid intolerance in obese Zucker rats," American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 289, no. 4, pp. R938-R946, 2005.

[18] E. W. Kraegen, D. E. James, A. B. Jenkins, and D. J. Chisholm, "Dose-response curves for in vivo insulin sensitivity in individual tissues in rats," The American Journal of Physiology, vol. 248, no. 3, pp. E353-E362, 1985.

[19] S. M. Furler, A. B. Jenkins, and E. W. Kraegen, "Effect of insulin on [3H]deoxy-D-glucose pharmacokinetics in the rat," The American Journal of Physiology, vol. 255, no. 6, pp. E806-E811, 1988.

[20] N. D. Oakes, A. Kjellstedt, G.-B. Forsberg et al., "Development and initial evaluation of a novel method for assessing tissue-specific plasma free fatty acid utilization in vivo using (R)-2bromopalmitate tracer," Journal of Lipid Research, vol. 40, no. 6, pp. 1155-1169, 1999.

[21] N. D. Oakes, P. Thalen, E. Aasum et al., "Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes," American Journal of Physiology: Endocrinology & Metabolism, vol. 290, no. 5, pp. E870-E881, 2006.

[22] V. P. Dole, "A relation between non-esterified fatty acids in plasma and the metabolism of glucose," The Journal of Clinical Investigation, vol. 35, no. 2, pp. 150-154, 1956.

[23] J. Folch, M. Lees, and G. H. Sloane Stanley, "A simple method for the isolation and purification of total lipides from animal tissues," The Journal of Biological Chemistry, vol. 226, no. 1, pp. 497-509, 1957.

[24] E. van Handel, "Estimation of glycogen in small amounts of tissue," Analytical Biochemistry, vol. 11, no. 2, pp. 256-265, 1965.

[25] A. B. Jenkins, S. M. Furler, and E. W. Kraegen, "2-deoxy-Dglucose metabolism in individual tissues of the rat in vivo," International Journal of Biochemistry, vol. 18, no. 4, pp. 311-318, 1986.

[26] N. D. Oakes, P. G. Thalen, S. M. Jacinto, and B. Ljung, "Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability," Diabetes, vol. 50, no. 5, pp. 1158-1165, 2001.

[27] L. C. Groop, R. C. Bonadonna, S. Del Prato et al., "Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance," Journal of Clinical Investigation, vol. 84, no. 1, pp. 205-213, 1989.

[28] B. Fagerberg, S. Edwards, T. Halmos et al., "Tesaglitazar, a novel dual peroxisome proliferator-activated receptor [alpha]/[gamma] agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population," Diabetologia, vol. 48, no. 9, pp. 1716-1725, 2005.

[29] B. Fagerberg, H. Schuster, G. S. Birketvedt, S. Tonstad, K. P. Ohman, and I. Gause-Nilsson, "Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPAR[alpha]/[gamma] agonist, tesaglitazar," Diabetes & Vascular Disease Research, vol. 4, no. 3, pp. 174-180, 2007

[30] B. J. Goldstein, J. Rosenstock, D. Anzalone, C. Tou, and K. P. (Ohman, "Effect of tesaglitazar, a dual PPAR[alpha]/[gamma] agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial," Current Medical Research and Opinion, vol. 22, no. 12, pp. 2575-2590, 2006.

[31] L. Bowen, P. P. Stein, R. Stevenson, and G. I. Shulman, "The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats," Metabolism, vol. 40, no. 10, pp. 1025-1030, 1991.

[32] Y. Miyazaki, A. Mahankali, M. Matsuda et al., "Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone," Diabetes Care, vol. 24, no. 4, pp. 710-719, 2001.

[33] N. D. Oakes, A. Kjellstedt, P. Thalen, B. Ljung, and N. Turner, "Roles of fatty acid oversupply and impaired oxidation in lipid accumulation in tissues of obese rats," Journal of Lipids, vol. 2013, Article ID 420754, 12 pages, 2013.

[34] B. D. Hegarty, S. M. Furler, N. D. Oakes, E. W. Kraegen, and G. J. Cooney, "Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPAR[alpha]/[gamma] agonist tesaglitazar," Endocrinology, vol. 145, no. 7, pp. 3158-3164, 2004.

[35] Z. Chen, P. A. Vigueira, K. T. Chambers et al., "Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor [gamma]-sparing thiazolidinedione," Journal of Biological Chemistry, vol. 287, pp. 23537-23548, 2012.

[36] A. S. Divakaruni, S. E. Wiley, G. W. Rogers et al., "Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, pp. 5422-5427, 2013.

[37] T. J. Chahil and H. N. Ginsberg, "Diabetic dyslipidemia," Endocrinology & Metabolism Clinics of North America, vol. 35, no. 3, pp. 491-510, 2006.

[38] T. K. T. Lam, A. Carpentier, G. F. Lewis, G. van de Werve, I. G. Fantus, and A. Giacca, "Mechanisms of the free fatty acid-induced increase in hepatic glucose production," American Journal of Physiology: Endocrinology & Metabolism, vol. 284, no. 5, pp. E863-E873, 2003.

[39] V. T. Samuel and G. I. Shulman, "Mechanisms for insulin resistance: common threads and missing links," Cell, vol. 148, no. 5, pp. 852-871, 2012.

[40] H. Schuster, B. Fagerberg, S. Edwards et al., "Tesaglitazar, a dual peroxisome proliferator-activated receptor a/y agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance," Atherosclerosis, vol. 197, no. 1, pp. 355-362, 2008.

[41] N. D. Oakes, B. Ljung, and G. Camejo, "Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor y agonists," Journal of the Royal Society of Medicine, vol. 95, no. 42, pp. 33-38, 2002.

[42] R. E. Ratner, S. Parikh, and C. Tou, "Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes," Diabetes & Vascular Disease Research, vol. 4, no. 3, pp. 214-221, 2007

[43] J. W. A. van der Hoorn, J. W. Jukema, L. M. Havekes et al., "The dual PPAR[alpha]/[gamma] agonist tesaglitazar blocks progression of preexisting atherosclerosis in APOE*3Leiden.CETP transgenic mice," British Journal of Pharmacology, vol. 156, no. 7, pp. 1067-1075, 2009.

[44] E. C. Chira, T. S. McMillen, S. Wang et al., "Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice," Atherosclerosis, vol. 195, no. 1, pp. 100-109, 2007.

Kristina Wallenius, Ann Kjellstedt, Pia Thalen, Lars Lofgren, and Nicholas D.

Oakes

AstraZeneca R&D Molndal, 431 83 Molndal, Sweden

Correspondence should be addressed to Kristina Wallenius;

kristina.wallenius@astrazeneca.com

Received 1 July 2013; Revised 27 August 2013; Accepted 27 August 2013

Academic Editor: Brian Finck

TABLE 1: Whole body and tissue specific fluxes of glucose and FFA.

Abbreviation                    Measures

Study 1
  [R.sub.d]              Glucose disposal rate
  HGO                    Hepatic glucose output
Study 2
  [R.sub.d]'          Glucose disposal rate index
  [R.sub.g]'        Tissue glucose utilization index
Study 3
  [[??].sub.d]           Glucose disposal rate
  [R.sub.fa]              FFA appearance rate
  [K.sub.fa]               FFA clearance rate
  [R.sub.g]'        Tissue glucose utilization index
  [R.sub.gly]        Tissue glycogen synthesis rate
  [R.sub.f.sup.*]     Tissue FFA utilization index
  [K.sub.f.sup.*]         Tissue FFA clearance
  [R.sub.fs]               Tissue FFA storage

Abbreviation             Tracer

Study 1
  [R.sub.d]         [sup.3]H-Glucose
  HGO               [sup.3]H-Glucose
Study 2
  [R.sub.d]'          [sup.3]H-2DG
  [R.sub.g]'          [sup.3]H-2DG
Study 3
  [[??].sub.d]      [sup.13]C-Glucose
  [R.sub.fa]           [sup.14]C-P
  [K.sub.fa]           [sup.14]C-P
  [R.sub.g]'          [sup.14]C-2DG
  [R.sub.gly]       [sup.13]C-Glucose
  [R.sub.f.sup.*]    [sup.3]H-R-BrP
  [K.sub.f.sup.*]      [sup.14]C-P
  [R.sub.fs]           [sup.14]C-P

Abbreviation                           Comment

Study 1
  [R.sub.d]         Best [R.sub.d] estimate, tracer steady-state
  HGO                           HGO = [R.sub.d] - GIR
Study 2
  [R.sub.d]'          Approx [R.sub.d] value, analog transient
  [R.sub.g]'
Study 3
  [[??].sub.d]        Approx [R.sub.d] value, tracer transient
  [R.sub.fa]
  [K.sub.fa]
  [R.sub.g]'
  [R.sub.gly]
  [R.sub.f.sup.*]
  [K.sub.f.sup.*]
  [R.sub.fs]

TABLE 2: Body weights, plasma glucose levels and steady state clamp
GIRs in Lean, Obese and Tesaglitazar groups of Zucker rats used in
Study 1.

                                Lean                  Obese

Body weight (g)            380 [+ or -] 12     630 [+ or -] 12 ***
Basal glucose (mM)        6.1 [+ or -] 0.4     8.8 [+ or -] 0.3 **
Clamp glucose (mM)        5.5 [+ or -] 0.3     8.6 [+ or -] 0.4 **
GIR ([micro]mol/min/kg)   62.5 [+ or -] 5.9   20.0 [+ or -] 3.5 ***

                                  Tesaglitazar

Body weight (g)                  651 [+ or -] 18
Basal glucose (mM)              8.7 [+ or -] 0.9
Clamp glucose (mM)              8.3 [+ or -] 0.9
GIR ([micro]mol/min/kg)   80.0 [+ or -] 5.7 ([dagger])

Results are expressed as mean [+ or -] SE (n = 4-5). ** P < 0.01,
*** P < 0.001 versus Lean. ([dagger]) P < 0.05 versus Obese.

TABLE 3: Insulin infusion rates, steady state plasma insulin and
glucose levels, and GIRs needed to maintain isoglycemia during the
clamps used in Study 2.

Group              Insulin infusion              Insulin
Body weight (g)   (pmol/[kg.sub.lbm]/              (nM)
                         min)

Lean 396 [+ or -] 13

  Basal                    0                 0.3 [+ or -] 0.1
  ClampL                  30                 1.1 [+ or -] 0.1
  ClampH                  300               22.3 [+ or -] 3.2

Obese 583 [+ or -] 21 ***

  Basal                    0               6.2 [+ or -] 1.1 ***
  ClampL                  120             11.4 [+ or -] 1.2 ***
  ClampH                 1200               125 [+ or -] 24 **

Tesaglitazar 654 [+ or -] 13 ([dagger])

  Basal                    0                 0.6[+ or -] 0.1
                                        ([dagger][dagger][dagger])
  ClampL                  60                 2.1 [+ or -] 0.1
                                        ([dagger][dagger][dagger])

  ClampM                  210               10.0 [+ or -] 0.8


  ClampH                  600              47.1 [+ or -] 9.1tt
                                            ([dagger][dagger])

Group                    Glucose                   GIR
Body weight (g)           (mM)             ([micro]mol/min/kg)

Lean 396 [+ or -] 13

  Basal             6.7 [+ or -] 0.3                0
  ClampL            6.5 [+ or -] 0.4        77.3 [+ or -] 6.8
  ClampH            6.5 [+ or -] 0.2       152.7 [+ or -] 10.9

Obese 583 [+ or -] 21 ***

  Basal           9.8 [+ or -] 0.4 ***              0
  ClampL          10.0 [+ or -] 0.3 ***   28.3 [+ or -] 5.7 ***
  ClampH            9.7 [+ or -] 1.8      41.2 [+ or -] 13.9 ***

Tesaglitazar 654 [+ or -] 13 ([dagger])

  Basal             8.8 [+ or -] 0.4                0

  ClampL            8.7 [+ or -] 0.4t     105.4 [+ or -] 5.8
                       ([dagger])           ([dagger][dagger]
                                                [dagger])
  ClampM            9.5 [+ or -] 0.6      142.6 [+ or -] 9.6
                                            ([dagger][dagger]
                                                [dagger])
  ClampH            9.8 [+ or -] 1.1      150.5 [+ or -] 10.9
                                            ([dagger][dagger]
                                                [dagger])

ClampL performed at a physiological (postprandial) level of
hyperinsulinemia, ClampH at supraphysiological insulin levels,
ClampM (Tesaglitazar group only) designed to achieve plateau
insulin levels corresponding to those in Obese ClampL group.
Results are expressed as mean [+ or -] SE (n = 5-7). ** P < 0.01,
and *** P < 0.001 versus corresponding state of Lean. ([dagger]) <
0.05, ([dagger][dagger]) P < 0.01, and ([dagger][dagger][dagger]) P
< 0.001 versus corresponding state of Obese.

TABLE 4: Tissue-specific glucose utilization rates ([R'.sub.g],
[micro]mol/100g/min) in the basal and insulin stimulated states
during hyperinsulinemic-isoglycemic clamp studies in Lean, Obese, and
Tesaglitazar groups of Zucker rats used in Study 2.

                         WQ                        RG

Lean
  Basal           1.4 [+ or -] 0.1          3.7 [+ or -] 0.4
  ClampL          4.9 [+ or -] 0.5          13.2 [+ or -] 1.9
  ClampH          13.3 [+ or -] 1.6         28.8 [+ or -] 2.9
Obese
  Basal          3.0 [+ or -] 0.3 **       7.4 [+ or -] 1.0 **
  ClampL         3.0 [+ or -] 0.2 **        8.2 [+ or -] 1.3
  ClampH        3.1 [+ or -] 0.5 ***      11.7 [+ or -] 3.1 ***
Tesaglitazar
  Basal           2.4 [+ or -] 0.2        3.8 [+ or -] 0.3 ***

  ClampL          3.4 [+ or -] 0.3          7.2 [+ or -] 0.6

  ClampM          9.3 [+ or -] 1.0          41.4 [+ or -] 4.6
               ([double dagger][double   ([double dagger][double
               dagger][double dagger])   dagger][double dagger])
  ClampH          6.9 [+ or -] 0.9*         27.6 [+ or -] 3.3
                                            ([dagger][dagger]
                                                [dagger])

                    White fat              Brown fat

Lean
  Basal         1.0 [+ or -] 0.1       20.3 [+ or -] 6.6
  ClampL        2.0 [+ or -] 0.2        108 [+ or -] 40
  ClampH        2.4 [+ or -] 0.4        115[+ or -] 12
Obese
  Basal        2.9 [+ or -] 0.3 **    5.8 [+ or -] 0.5 **
  ClampL       4.0 [+ or -] 0.4 **   10.7 [+ or -] 1.3 **
  ClampH        3.8 [+ or -] 0.2     11.7 [+ or -] 2.2 ***
Tesaglitazar
  Basal        4.3 [+ or -] 0.4**      3.6 [+ or -] 0.2
               ([dagger][dagger])
  ClampL        7.2 [+ or -] 0.6       13.8 [+ or -] 3.8
                ([dagger][dagger]
                    [dagger])
  ClampM        5.8 [+ or -] 0.7      25.3 [+ or -] 3.6**
                ([double dagger])      ([double dagger]
                                       [double dagger])
  ClampH       6.9 [+ or -] 0.9 **     31.0 [+ or -] 4.3
               ([dagger][dagger])

                      Diaphragm                   Heart

Lean
  Basal           13.5 [+ or -] 1.8         38.5 [+ or -] 3.9
  ClampL          45.9 [+ or -] 4.1        114.8 [+ or -] 8.3
  ClampH          67.1 [+ or -] 5.5         80.7 [+ or -] 8.5
Obese
  Basal           15.7 [+ or -] 1.8       18.6 [+ or -] 1.8 ***
  ClampL        23.9 [+ or -] 3.4 **      27.5 [+ or -] 3.0 ***
  ClampH        24.1 [+ or -] 5.3 ***       56.0 [+ or -] 15
Tesaglitazar
  Basal           14.3 [+ or -] 2.6         18.0 [+ or -] 2.4

  ClampL          51.9 [+ or -] 4.0         73.9 [+ or -] 6.3
                  ([dagger][dagger]         ([dagger][dagger]
                      [dagger])                 [dagger])
  ClampM          79.8 [+ or -] 4.9         62.5 [+ or -] 1.6
               ([double dagger][double   ([double dagger][double
               dagger][double dagger])   dagger][double dagger])
  ClampH          65.6 [+ or -] 3.7         64.7 [+ or -] 3.6
                  ([dagger][dagger]
                      [dagger])

                    Cerebellum

Lean
  Basal         15.1 [+ or -] 1.1
  ClampL        16.9 [+ or -] 0.9
  ClampH        16.5 [+ or -] 0.7
Obese
  Basal         17.2 [+ or -] 1.4
  ClampL       20.1 [+ or -] 1.4 *
  ClampH       20.2 [+ or -] 0.9 **
Tesaglitazar
  Basal         14.5 [+ or -] 1.2

  ClampL        16.7 [+ or -] 0.6
                    ([dagger])

  ClampM        18.5 [+ or -] 1.3

  ClampH        17.4 [+ or -] 0.7
                    ([dagger])

Results are expressed as mean [+ or -] SE (n = 5-7). WQ, white
quadriceps muscle. RG, red gastrocnemius muscle. White fat represents
the epididymal fat pad. Brown fat represents interscapular brown
adipose depot. * P < 0.05, ** P < 0.01, and *** P < 0.001 versus
corresponding state of Lean. ([dagger]) P < 0.05, ([dagger][dagger])
P < 0.01, and ([dagger][dagger][dagger]) P < 0.001 versus
corresponding state of Obese. ([double dagger]) P < 0.05,
([double dagger][double dagger]) P < 0.01, and ([double dagger]
[double dagger][double dagger]) P < 0.001 versus ClampL Obese group.

TABLE 5: Body weights, plasma factors, and whole body glucose and
FFA metabolic turnover parameters in Lean, Obese, and Tesaglitazar
groups of Zucker rats studied under basal and clamp conditions used
in Study 3.

Group                                     Lean
State

                               Basal                  ClampL

Body weight (g)         407 [+ or -] 11 ***      405 [+ or -] 20
Insulin (nM)           0.74 [+ or -] 0.16 ***   1.10 [+ or -] 0.10

FFA (mM)               0.42 [+ or -] 0.03 ***   0.08 [+ or -] 0.01

[K.sub.fa](mL/min)       17.4 [+ or -] 2.1      25.8 [+ or -] 1.5
[R.sub.fa]              7.2 [+ or -] 1.0 ***     2.0 [+ or -] 0.1
  ([micro]mol/min)

Glucose (mM)            7.4 [+ or -] 0.2 **      7.7 [+ or -] 0.3
GIR ([micro]mol/min)             0              26.1 [+ or -] 2.4

[[??].sub.d]             19.0 [+ or -] 2.2 **    47.6 [+ or -] 1.2
  ([micro]mol/min)

Group                                    Obese
State

                             Basal                 ClampL

Body weight (g)         603 [+ or -] 14       582 [+ or -] 18
Insulin (nM)           5.88 [+ or -] 0.67   13.61 [+ or -] 2.60
                                                 ([dagger])
FFA (mM)               0.89 [+ or -] 0.05    0.63 [+ or -] 0.09

[K.sub.fa](mL/min)     20.7 [+ or -] 2.3     28.3 [+ or -] 1.6
[R.sub.fa]             18.9 [+ or -] 2.8     18.1 [+ or -] 3.2
  ([micro]mol/min)

Glucose (mM)           11.1 [+ or -] 1.0     11.6 [+ or -] 1.3
GIR ([micro]mol/min)           0            8.9 [+ or -] 2.7
                                             ([dagger][dagger]
                                                 [dagger])

[[??].sub.d]            36.0 [+ or -] 3.5    41.2 [+ or -] 2.0
  ([micro]mol/min)                           ([dagger][dagger])

Group                                  Tesaglitazar
State

                               Basal                  ClampL

Body weight (g)           666 [+ or -] 30        664 [+ or -] 27
Insulin (nM)           0.67 [+ or -] 0.07 ***   2.25 [+ or -] 0.10
                                                ([double dagger])
FFA (mM)                 0.81 [+ or -] 0.04     0.10 [+ or -] 0.01
                                                ([double dagger])
[K.sub.fa](mL/min)     38.4 [+ or -] 2.2 ***    47.1 [+ or -] 2.5
[R.sub.fa]              31.0 [+ or -] 3.0 *      4.6 [+ or -] 0.5
  ([micro]mol/min)                               ([double dagger]
                                                 [double dagger])
Glucose (mM)             11.8 [+ or -] 0.5      10.0 [+ or -] 0.4
GIR ([micro]mol/min)             0              66.9 [+ or -] 9.2
                                                 ([double dagger]
                                                 [double dagger]
                                                 [double dagger])
[[??].sub.d]             36.2 [+ or -] 3.1      101.8 [+ or -] 6.9
  ([micro]mol/min)                               ([double dagger]
                                                 [double dagger])

Results are mean [+ or -] SE (n = 6-9). Zucker rats were studied in
the 5 h fasted state. Groups of animals were studied either in the
basal state or during isoglycemic clamps performed at physiological
levels of hyperinsulinemia suited to each group (insulin infusion
rates as for ClampL in Study 2, defined in Table 3). Basal
state differences; * P < 0.05, ** P < 0.01, and *** p < 0.001 versus
obese. Response to insulin (ClampL-Basal) differences; ([dagger])
P < 0.05, ([dagger][dagger]) P < 0.01, and ([dagger][dagger][dagger])
P < 0.001 Obese versus Lean, ([double dagger]) P < 0.05,
([double dagger][double dagger]) P < 0.01, and ([double dagger]
[double dagger] [double dagger]) P < 0.001 Tesaglitazar versus Obese.

TABLE 6: Tissue-specific rates of FFA incorporation into
storage [R.sub.fs] ([micro]mol/100 g/min).

Group                             Lean
State

                      Basal                  ClampL

Red gastroc    0.68 [+ or -] 0.10 *    0.32 [+ or -] 0.02

White fat       0.84 [+ or -] 0.20     0.13 [+ or -] 0.03

Heart          4.7 [+ or -] 0.5 ***     4.6 [+ or -] 0.5
Cerebellum    0.32 [+ or -] 0.02 ***   0.09 [+ or -] 0.01

Liver         24.8 [+ or -] 1.0 ***     5.4 [+ or -] 0.5

Group                           Obese
State

                    Basal                ClampL

Red gastroc   1.81 [+ or -] 0.44   2.19 [+ or -] 0.25

White fat     1.15 [+ or -] 0.14   1.15 [+ or -] 0.22

Heart         12.3 [+ or -] 1.6    15.3 [+ or -] 1.4
Cerebellum    0.64 [+ or -] 0.09   0.58 [+ or -] 0.11

Liver         37.7 [+ or -] 3.9    31.1 [+ or -] 3.4
                                       ([dagger])

Group                        Tesaglitazar
State

                      Basal                 ClampL

Red gastroc    1.68 [+ or -] 0.30     0.41 [+ or -] 0.02
                                       ([double dagger]
                                       [double dagger])
White fat     1.90 [+ or -] 0.25 **   0.32 [+ or -] 0.05
                                       ([double dagger]
                                       [double dagger]
                                       [double dagger])
Heart         4.8 [+ or -] 0.3 ***     4.9 [+ or -] 0.3
Cerebellum     0.52 [+ or -] 0.05     0.09 [+ or -] 0.01
                                       ([double dagger]
                                       [double dagger])
Liver          45.7 [+ or -] 4.1 *     7.2 [+ or -] 0.9
                                       ([double dagger]
                                       [double dagger]
                                       [double dagger])

Results are mean [+ or -] SE (n = 6-8). Groups of animals were
studied either in the basal state or during isoglycemic clamps
performed at physiological levels of hyperinsulinemia suited to
each group (insulin infusion rates as for ClampL in Study 2,
defined in Table 3). Red gastroc abbreviation for red gastrocnemius.
Basal state differences; * P < 0.05, ** P < 0.01, and *** P < 0.001
versus obese. Response to insulin (ClampL-Basal) differences;
([dagger]) < 0.05 Obese versus Lean and ([double dagger][double
dagger]) P < 0.01, ([double dagger][double dagger][double dagger])
P < 0.001 Tesaglitazar versus Obese.

TABLE 7: Glycogen content ([micro]mol/g) and synthesis rate
[R.sub.gly] ([micro]mol/100 g/min) in red skeletal muscle.

Group                    Lean
State

                Basal                ClampL

Content     33 [+ or -] 4        40 [+ or -] 2
%         0.25 [+ or -] 0.05   3.53 [+ or -] 0.91

Group                    Obese
State

                Basal               ClampL

Content     43 [+ or -]7        49 [+ or -] 2
%         0.38 [+ or -]0.07   1.86 [+ or -] 0.55
                                ([dagger])

Group                Tesaglitazar
State

                Basal                 ClampL

Content     33 [+ or -] 3 *      41 [+ or -] 2
%         0.20 [+ or -] 0.02   3.99 [+ or -] 0.31 **

Results are mean [+ or -] SE (n = 4-8). Groups of animals
were studied either in the basal state or during isoglycemic
clamps performed at physiological levels of hyperinsulinemia
suited to each group (insulin infusion rates as for ClampL in
Study 2, defined in Table 3). Data represent values obtained
by averaging red gastrocnemius and red quadriceps muscles.
Basal state differences; * P < 0.05 versus Obese. Response to
insulin (ClampL-Basal) differences; ([dagger]) P < 0.05 Obese
versus Lean, and ** P < 0.01, Tesaglitazar versus Obese.
COPYRIGHT 2013 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Wallenius, Kristina; Kjellstedt, Ann; Thalen, Pia; Lofgren, Lars; Oakes, Nicholas D.
Publication:PPAR Research
Article Type:Report
Date:Jan 1, 2013
Words:11182
Previous Article:Expression and function of PPARs in placenta.
Next Article:PPAR[gamma] regulates genes involved in triacylglycerol synthesis and secretion in mammary gland epithelial cells of dairy goats.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters